Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
NCT00986713Phase 4Unknown
- Sponsor
- Capital Medical University
- Start
- Jun 2008
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of amphotericin b in Invasive Pulmonary Aspergillosis (IPA) (2 arms), sponsored by Capital Medical University. Primary endpoint: Incidence of Invasive Pulmonary Aspergillosis at 3 years. Status: unknown.
02
Drugs
amphotericin b
03
Conditions
Invasive Pulmonary Aspergillosis (IPA)
Beyond the preview
Go deeper on NCT00986713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00986713.